IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 598,100 shares, a drop of 22.7% from the February 13th total of 773,300 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average trading volume of 385,300 shares, the days-to-cover ratio is presently 1.6 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Wednesday, November 27th.

IceCure Medical Price Performance

ICCM stock traded up $0.08 during mid-day trading on Monday, hitting $1.50. The stock had a trading volume of 357,931 shares, compared to its average volume of 510,771. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The firm has a market capitalization of $82.98 million, a P/E ratio of -5.16 and a beta of 0.37. The firm has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $0.95.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC grew its stake in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,453 shares of the company’s stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.